Latest news: Committee votes to restart J&J vaccinations, checkpoint giants prep defense, underdog vaccine enters the spotlight, and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
If this report was helpful in recapping it all for you, please do share it with your colleagues.
Resume J&J vaccinations, committee votes
The verdict is in: A CDC advisory committee voted late Friday to restart vaccinations with J&J’s Covid-19 vaccine, which is on a hiatus following reports of rare but potentially life-threatening blood clots. They stopped short of restricting its use to specific populations or specifying a new warning; however, J&J noted ahead of the vote that it has agreed to add a warning to the label regarding the risks, which they said is concentrated in females ages 18 through 49 years and possibly linked to its vaccine. In total, the CDC said it has now spotted 15 cases of the blood clots with low platelets — with more under investigation.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.